Legend Biotech Corporation is a biopharmaceutical company that focuses on developing novel cell therapies for a range of indications. Its lead product is LCAR-B38M, which is designed to treat multiple myeloma and is currently undergoing clinical trials. The company also has a portfolio of autologous product candidates that are in Phase I clinical trials, as well as product candidates in early preclinical and clinical development for solid tumors and infectious diseases.